Moleculera Biosciences

Moleculera Labs is a biotechnology startup established in 2011, based in the United States. The company's slogan "Pioneering Research. Life-Changing Tests." reflects its dedication to advancing research in autoimmune neurobiology. Moleculera Labs operates a fully-accredited CLIA/COLA clinical laboratory and specializes in providing advanced testing services. Their flagship offering, The Cunningham Panel™, assists physicians in diagnosing autoimmune-based neuropsychiatric disorders, such as obsessive-compulsive behaviors, tics, anxiety, attention deficit hyperactivity disorder, and behaviors related to Autism Spectrum Disorders caused by molecular mimicry triggered by common infections. This groundbreaking testing service has garnered significant attention in the medical community. Moreover, Moleculera Labs is actively involved in research focused on the autoimmune nature of other neuropsychiatric conditions, including depression, schizophrenia, and bipolar disorder. The company received a notable $1.06M Venture Round investment on 19 May 2015 from investors SeedStep Angels, i2E, i2i, Inc. This investment underscores the confidence of venture capital firms in the potential impact of Moleculera Labs' pioneering research and diagnostic services in the field of autoimmune neurobiology. With its innovative approach and strong investor backing, Moleculera Labs is poised to bring about significant advancements in the diagnosis and treatment of autoimmune-based neuropsychiatric disorders, promising to make a substantial impact on the healthcare industry.